Literature DB >> 36266403

Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT.

Maja Guberina1,2, Ken Herrmann3,4, Christoph Pöttgen5, Nika Guberina5, Hubertus Hautzel3,4, Thomas Gauler5, Till Ploenes6, Lale Umutlu7, Axel Wetter7, Dirk Theegarten8, Clemens Aigner6, Wilfried E E Eberhardt9,10, Martin Metzenmacher9,10, Marcel Wiesweg9,10, Martin Schuler3,9,10, Rüdiger Karpf-Wissel11, Alina Santiago Garcia5, Kaid Darwiche11, Martin Stuschke5,3.   

Abstract

Accurate determination of lymph-node (LN) metastases is a prerequisite for high precision radiotherapy. The primary aim is to characterise the performance of PET/CT-based machine-learning classifiers to predict LN-involvement by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in stage-III NSCLC. Prediction models for LN-positivity based on [18F]FDG-PET/CT features were built using logistic regression and machine-learning models random forest (RF) and multilayer perceptron neural network (MLP) for stage-III NSCLC before radiochemotherapy. A total of 675 LN-stations were sampled in 180 patients. The logistic and RF models identified SUVmax, the short-axis LN-diameter and the echelon of the considered LN among the most important parameters for EBUS-positivity. Adjusting the sensitivity of machine-learning classifiers to that of the expert-rater of 94.5%, MLP (P = 0.0061) and RF models (P = 0.038) showed lower misclassification rates (MCR) than the standard-report, weighting false positives and false negatives equally. Increasing the sensitivity of classifiers from 94.5 to 99.3% resulted in increase of MCR from 13.3/14.5 to 29.8/34.2% for MLP/RF, respectively. PET/CT-based machine-learning classifiers can achieve a high sensitivity (94.5%) to detect EBUS-positive LNs at a low misclassification rate. As the specificity decreases rapidly above that level, a combined test of a PET/CT-based MLP/RF classifier and EBUS-TBNA is recommended for radiation target volume definition.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36266403      PMCID: PMC9584941          DOI: 10.1038/s41598-022-21637-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  37 in total

1.  Basic principles of ROC analysis.

Authors:  C E Metz
Journal:  Semin Nucl Med       Date:  1978-10       Impact factor: 4.446

2.  Improving diagnostic performance of 18F-FDG-PET/CT for assessment of regional nodal involvement in non-small cell lung cancer.

Authors:  D D Yang; E Mirvis; J Goldring; A R C Patel; T Wagner
Journal:  Clin Radiol       Date:  2019-08-13       Impact factor: 2.350

3.  Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS).

Authors:  Peter Vilmann; Paul Frost Clementsen; Sara Colella; Mette Siemsen; Paul De Leyn; Jean-Marc Dumonceau; Felix J Herth; Alberto Larghi; Enrique Vazquez-Sequeiros; Cesare Hassan; Laurence Crombag; Daniël A Korevaar; Lars Konge; Jouke T Annema
Journal:  Endoscopy       Date:  2015-06-10       Impact factor: 10.093

4.  Deep Learning in Medicine-Promise, Progress, and Challenges.

Authors:  Fei Wang; Lawrence Peter Casalino; Dhruv Khullar
Journal:  JAMA Intern Med       Date:  2019-03-01       Impact factor: 21.873

5.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

6.  Application of a neural network to improve nodal staging accuracy with 18F-FDG PET in non-small cell lung cancer.

Authors:  Hubert Vesselle; Eric Turcotte; Linda Wiens; David Haynor
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

Review 7.  Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.

Authors:  Michael K Gould; Ware G Kuschner; Chara E Rydzak; Courtney C Maclean; Anita N Demas; Hidenobu Shigemitsu; Jo Kay Chan; Douglas K Owens
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391

8.  Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT.

Authors:  Shaolei Li; Qingfeng Zheng; Yuanyuan Ma; Yuzhao Wang; Yuan Feng; Bingtian Zhao; Yue Yang
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

9.  Comparison of machine learning methods for classifying mediastinal lymph node metastasis of non-small cell lung cancer from 18F-FDG PET/CT images.

Authors:  Hongkai Wang; Zongwei Zhou; Yingci Li; Zhonghua Chen; Peiou Lu; Wenzhi Wang; Wanyu Liu; Lijuan Yu
Journal:  EJNMMI Res       Date:  2017-01-28       Impact factor: 3.138

Review 10.  Value of PET imaging for radiation therapy.

Authors:  Constantin Lapa; Ursula Nestle; Nathalie L Albert; Christian Baues; Ambros Beer; Andreas Buck; Volker Budach; Rebecca Bütof; Stephanie E Combs; Thorsten Derlin; Matthias Eiber; Wolfgang P Fendler; Christian Furth; Cihan Gani; Eleni Gkika; Anca-L Grosu; Christoph Henkenberens; Harun Ilhan; Steffen Löck; Simone Marnitz-Schulze; Matthias Miederer; Michael Mix; Nils H Nicolay; Maximilian Niyazi; Christoph Pöttgen; Claus M Rödel; Imke Schatka; Sarah M Schwarzenboeck; Andrei S Todica; Wolfgang Weber; Simone Wegen; Thomas Wiegel; Constantinos Zamboglou; Daniel Zips; Klaus Zöphel; Sebastian Zschaeck; Daniela Thorwarth; Esther G C Troost
Journal:  Strahlenther Onkol       Date:  2021-07-14       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.